Payment overview · 2025
General Payments
$531.96
29 reported records · 10 companies
Healthcare provider profile · identity verified
Eric A Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WOOSTER, OH · NPI 1972533214
Verified facts
What the public records show
CMS Open Payments records show Eric A Smith, M.D. received $531.96 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $217.44 | 40.9% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.76 | 17.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.79 | 11.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.04 | 8.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.64 | 5.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.64 | 4.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.61 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.47 | 3.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.09 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.48 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $531.96 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.47 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.41 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.79 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.79 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.09 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 86 |
| Lisinopril | Lisinopril | 188 | 57 |
| Losartan Potassium | Losartan Potassium | 188 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 41 |
| Omeprazole | Omeprazole | 164 | 39 |
| Metformin Hcl | Metformin Hcl | 163 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 47 |
| Ramipril | Ramipril | 149 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 40 |
| Famotidine | Famotidine | 127 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 34 |
| Gabapentin | Gabapentin | 116 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 35 |
| Furosemide | Furosemide | 107 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 104 | 60 |
| Telmisartan | Telmisartan | 103 | 30 |
| Eliquis | Apixaban | 92 | 23 |
| Sertraline Hcl | Sertraline Hcl | 91 | 21 |
| Tramadol Hcl | Tramadol Hcl | 90 | 24 |
| Allopurinol | Allopurinol | 87 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 29 |
| Farxiga | Dapagliflozin Propanediol | 85 | 20 |
| Mirtazapine | Mirtazapine | 83 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 27 |
| Metformin Hcl Er | Metformin Hcl | 79 | 18 |
| Montelukast Sodium | Montelukast Sodium | 78 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 19 |
| Irbesartan | Irbesartan | 74 | 19 |
| Synthroid | Levothyroxine Sodium | 74 | 21 |
| Indapamide | Indapamide | 73 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 18 |
| Potassium Citrate Er | Potassium Citrate | 73 | 21 |
| Meloxicam | Meloxicam | 69 | 28 |
| Atenolol | Atenolol | 68 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 22 |
| Alendronate Sodium | Alendronate Sodium | 63 | 19 |
| Carvedilol | Carvedilol | 61 | 17 |
| Finasteride | Finasteride | 61 | 14 |
| Simvastatin | Simvastatin | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 18 |
| Nabumetone | Nabumetone | 54 | 21 |
| Trazodone Hcl | Trazodone Hcl | 54 | 13 |
| Warfarin Sodium | Warfarin Sodium | 53 | 11 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 21 |
| Prednisone | Prednisone | 49 | 41 |
| Jardiance | Empagliflozin | 48 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 13 |
| Bupropion Xl | Bupropion Hcl | 44 | 16 |
| Spironolactone | Spironolactone | 44 | 16 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 43 | 14 |
| Azithromycin | Azithromycin | 39 | 32 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 30 | 30 |
| Baclofen | Baclofen | 30 | suppressed |
| Cefdinir | Cefdinir | 30 | 28 |
| Cephalexin | Cephalexin | 30 | 26 |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 13 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | 11 |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Febuxostat | Febuxostat | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Euthyrox | Levothyroxine Sodium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Temazepam | Temazepam | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $531.96 · 29 records | ABBVIE INC. | CAPVAXIVE, CREON, ELIQUIS, GARDASIL 9, ID NOW INSTRUMENT, JARDIANCE, JASCAYD, Korlym, LINZESS, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error